Contract Research & Services
Contract Research

Biosimilars in Emerging Markets Is It A Level Playing Field?

Published 27 April 2015 | By PRA Health Sciences

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need.

Available Downloads

Biosimilars in Emerging Markets Is It A Level Playing Field?